Part I: Pharmacological bases of metronomic chemotherapy: The metronomic concept -- Antiangiogenic effects of metronomic chemotherapy -- Effects of metronomic chemotherapy on immunity -- Other proposed mechanism of action of metronomic chemotherapy. Part II: Preclinical studies of metronomic chemotherapy: Alkylating agents -- Camptothecins -- Fluoropyrimidines -- Taxanes -- Vinca alkaloids -- Anthracyclines -- Other drugs -- Part III. Drugs combined with metronomic chemotherapy in preclinical studies: Tyrosine kinase inhibitors -- Monoclonal antibodies -- Tumor vaccines -- Other drugs. Part IV. Clinical activity of metronomic chemotherapy: Breast cancers -- Prostate cancers -- Gastrointestinal cancers -- CNS cancers -- Pediatric malignancies -- Sarcomas -- Hematological cancers -- Liver cancers -- Gynecologic Cancers -- Lung cancers -- Other cancers. Part V: Clinical Pharmacology of metronomic chemotherapy: Pharmacokinetics of metronomic chemotherapy -- Pharmacodynamics of metronomic chemotherapy -- Pharmacogenetics of metronomic chemotherapy -- Pharmacoeconomics of metronomic chemotherapy and its social impact -- Adverse drug reactions of metronomic chemotherapy. Part VI:  Metronomic chemotherapy in veterinarian clinic: Clinical studies of metronomic chemotherapy alone -- Clinical studies of metronomic chemotherapy and other drugs.

This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoenconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.